Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Greatbatch Organizes for Accelerated Growth

June 05 2013

FRISCO, Texas--(BUSINESS WIRE)--Jun. 5, 2013-- Greatbatch, Inc. (NYSE:GB) today announced a realignment of its operating structure to optimize its continued focus on profitable growth. Greatbatch Medical and Electrochem Solutions today operate independent operations and sales & marketing groups; those will now be combined into singular sales & marketing and operations groups serving the entire Greatbatch organization.

“We’ve spent the past eight years successfully integrating and consolidating our organization. With that mission accomplished, we can set our sights squarely on our growth target to achieve 5 percent organic growth or better,” said Greatbatch President & Chief Executive Officer Thomas J. Hook. “As we shared with investors earlier this year, the company is progressing from strictly a developer of components and sub-assemblies to an organization capable of developing complete medical devices for OEM customers. Our realignment into a more unified Greatbatch will allow us to reinvest in both our core business as well as emerging platforms in pursuit of substantial growth.”

Four senior executives have been appointed to new positions in the company:

  • Andrew Holman, formerly vice president, Global Sales & Marketing, Orthopaedic Product Development, Greatbatch Medical, is named executive vice president, Global Sales & Marketing, Greatbatch, Inc.;
  • Mauricio Arellano, formerly president, Greatbatch Medical, is named executive vice president, Global Operations, Greatbatch, Inc.;
  • Susan Bratton, formerly president, Electrochem Solutions, is named executive vice president, Business Development, Greatbatch, Inc.;
  • And George Cintra, formerly vice president, Research Development and Engineering, Electrochem Solutions, is named senior vice president and chief technology officer, Greatbatch, Inc.

As announced at its Investor Day this past March, Greatbatch is leveraging its portfolio of more than 1,000 patents to more fully tap the potential of its multi-billion dollar end markets, specifically in cardiac and neuromodulation, portable medical, vascular and orthopaedics. Eighty-eight percent of its revenues are currently derived from the medical device sector.

“We fully anticipate that this realignment will have a positive short-term and long-term impact on our financial results. Under our plan, the Company expects to incur restructuring charges in the range of $4.2 to $5.0 million, which will include employee severance and termination benefits,” said Greatbatch Senior Vice President and Chief Financial Officer Michael Dinkins. “When fully implemented, this plan is expected to result in annual savings of approximately $7.0 to $7.7 million. Based on the short-term impact of this realignment and our current view of the balance of the year’s financial results, we are raising our adjusted diluted earnings per share guidance range to $2.00 to $2.05 per share from the previous range of $1.90 to $2.00 per share. These results exclude the impact of the restructuring charges mentioned above.”

The company will provide its normal guidance update with its 2nd quarter earnings release.

About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to industries that depend on reliable, long-lasting performance. The company develops and manufactures critical medical device technologies for the cardiac, neuromodulation, vascular and orthopaedic markets; and batteries for high-end niche applications in the portable medical, energy, military, and other markets. Additional information is available at www.greatbatch.com.

Forward-Looking Statements

Some of the statements in this press release, including the expected cost savings resulting from the announced realignment and the information provided on its adjusted diluted earnings per share guidance, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or variations or the negative of these terms or other comparable terminology. These statements are based on the Company’s current expectations. The Company’s actual results could differ materially from those stated or implied in such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements include, among others, the following matters affecting the Company: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing/vertical integration pressure from customers; our ability to timely and successfully implement our cost reduction and plant consolidation initiatives (including the consolidation of our Swiss orthopaedic operations); our reliance on third party suppliers for raw materials, products and subcomponents; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies; our unsuccessful expansion into new markets; our ability to realize a return on our substantial RD&E investments, including system and device products; changes in and challenges related to compliance with governmental laws and regulations, including regulations of the U.S. Food and Drug Administration and foreign government agencies regulating medical device approvals; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions and other risks and uncertainties described in the Company’s Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking information in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Source: Greatbatch, Inc.

Greatbatch, Inc.
Investor Relations:
Elizabeth Cowell, 214-618-4982
Christopher Knospe, 716-759-5727